• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    2/14/22 3:03:17 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OMER alert in real time by email
    SC 13G/A 1 schedule13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 2)*
     

     
    Omeros Corporation
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.01 per share
     
     
    (Title of Class of Securities)
     

     
    682143102
     
     
    (CUSIP Number)
     

     
    December 31, 2021
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Cormorant Global Healthcare Master Fund, LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    0 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    0 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
    PN (Partnership)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Global Healthcare GP, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    0 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    0 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Asset Management, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    0 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    0 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    0 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    0 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    IN (Individual)
     

    Item 1.
    (a)
    Name of Issuer
     
    Omeros Corporation
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    201 Elliot Avenue West, Seattle, Washington 98119

    Item 2.
    (a)
    Name of Person Filing
     
    Cormorant Global Healthcare Master Fund, LP
    Cormorant Global Healthcare GP, LLC
    Cormorant Asset Management, LP
    Bihua Chen
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
    (c)
    Citizenship
     
     
    Cormorant Global Healthcare Master Fund, LP - Cayman Islands
    Cormorant Global Healthcare GP, LLC - Delaware
    Cormorant Asset Management, LP - Delaware
    Bihua Chen - United States
     
    (d)
    Title of Class of Securities
     
    Common Stock
     
    (e)
    CUSIP Number
     
    682143102


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    [ ]
    Insurance Company as defined in Section 3(a)(19) of the Act
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned***
     
     
    Cormorant Global Healthcare Master Fund, LP – 0 shares
    Cormorant Global Healthcare GP, LLC – 0 shares
    Cormorant Asset Management, LP – 0 shares
    Bihua Chen – 0 shares
    (b)
    Percent of Class
     
     
    Cormorant Global Healthcare Master Fund, LP – 0%
    Cormorant Global Healthcare GP, LLC – 0%
    Cormorant Asset Management, LP – 0%
    Bihua Chen – 0%

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    Cormorant Global Healthcare Master Fund, LP - 0 shares
    Cormorant Global Healthcare GP, LLC - 0 shares
    Cormorant Asset Management, LP - 0 shares
    Bihua Chen - 0 shares
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    Cormorant Global Healthcare Master Fund, LP – 0 shares
    Cormorant Global Healthcare GP, LLC – 0 shares
    Cormorant Asset Management, LP – 0 shares
    Bihua Chen – 0 shares
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    Cormorant Global Healthcare Master Fund, LP - 0 shares
    Cormorant Global Healthcare GP, LLC - 0 shares
    Cormorant Asset Management, LP - 0 shares
    Bihua Chen - 0 shares
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    Cormorant Global Healthcare Master Fund, LP – 0 shares
    Cormorant Global Healthcare GP, LLC – 0 shares
    Cormorant Asset Management, LP – 0 shares
    Bihua Chen – 0 shares

    *** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”), as reported herein, and a managed account (the “Account”).  Cormorant Global Healthcare GP, LLC serves as the general partner of the Master Fund. Cormorant Asset Management, LP serves as the investment manager to the Master Fund and the Account.  Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and the general partner of Cormorant Asset Management, LP.  Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X  ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit

    99.1                  Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on May 4, 2020.

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
    February 14, 2022


    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
    By: Cormorant Global Healthcare GP, LLC
    its General Partner

    By: /s/ Bihua Chen
    Bihua Chen, Managing Member

    CORMORANT GLOBAL HEALTHCARE GP, LLC

    By: /s/ Bihua Chen
    Bihua Chen, Managing Member

    CORMORANT ASSET MANAGEMENT, LP
    By: Cormorant Asset Management GP, LLC
    its General Partner

    By: /s/ Bihua Chen
    Bihua Chen, Managing Member

    /s/ Bihua Chen
    Bihua Chen

    Get the next $OMER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMER

    DatePrice TargetRatingAnalyst
    6/10/2025$9.00Buy
    H.C. Wainwright
    12/23/2024$36.00Buy
    D. Boral Capital
    11/14/2024$9.00Buy
    Rodman & Renshaw
    12/8/2022$12.00 → $2.00Buy → Neutral
    UBS
    11/8/2022$8.00 → $3.00Neutral → Underperform
    BofA Securities
    6/8/2022$12.00 → $4.00Buy → Neutral
    BofA Securities
    10/19/2021$19.00 → $12.00Buy
    HC Wainwright & Co.
    10/8/2021Neutral → Underweight
    JP Morgan
    More analyst ratings

    $OMER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Omeros with a new price target

    H.C. Wainwright initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    6/10/25 8:09:22 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital initiated coverage on Omeros with a new price target

    D. Boral Capital initiated coverage of Omeros with a rating of Buy and set a new price target of $36.00

    12/23/24 7:27:28 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Omeros with a new price target

    Rodman & Renshaw initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    11/14/24 7:47:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Demopulos Gregory A Md bought $25,200 worth of shares (15,000 units at $1.68) (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/21/23 8:11:35 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Demopulos Peter A Md bought $15,300 worth of shares (10,000 units at $1.53), increasing direct ownership by 5% to 208,516 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/17/23 9:46:20 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    SEC Filings

    View All

    SEC Form 10-K filed by Omeros Corporation

    10-K - OMEROS CORP (0001285819) (Filer)

    3/31/26 4:06:16 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OMEROS CORP (0001285819) (Filer)

    3/31/26 4:05:19 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Omeros Corporation

    SCHEDULE 13G/A - OMEROS CORP (0001285819) (Subject)

    3/27/26 11:04:36 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

    – Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year. Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth

    3/31/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

    Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros' website. A replay of the call will be available for 90 days in the "Archived Events" section of the Inves

    3/26/26 8:45:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

    Omeros Corporation (NASDAQ:OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled "Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy," will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôpital Saint-Antoine, AP-HP, and will feature speakers Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, and Michelle L. Schoettler, MD, MS, Children's Healthcare of Atlanta. The EBMT Annual Meeting is a key eve

    3/21/26 3:23:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO & President Demopulos Gregory A Md exercised 400,000 shares at a strike of $10.27 and covered exercise/tax liability with 357,678 shares, increasing direct ownership by 3% to 1,469,308 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    2/20/26 9:40:28 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Finance & CAO Borges David J. sold $750,915 worth of shares (60,000 units at $12.52) and exercised 30,000 shares at a strike of $3.06, closing all direct ownership in the company (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    1/14/26 5:25:24 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, CEO & President Demopulos Gregory A Md gifted 600,000 shares and received a gift of 600,000 shares, decreasing direct ownership by 30% to 1,426,986 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    10/15/25 7:16:04 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Financials

    Live finance-specific insights

    View All

    Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

    – Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year. Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth

    3/31/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

    Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros' website. A replay of the call will be available for 90 days in the "Archived Events" section of the Inves

    3/26/26 8:45:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Announces New Date for YARTEMLEA® Approval Conference Call

    — Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th

    12/26/25 6:36:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Leadership Updates

    Live Leadership Updates

    View All

    Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

    Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch

    10/19/23 8:30:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    3/27/24 2:47:02 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    2/14/24 6:05:17 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Omeros Corporation

    SC 13G - OMEROS CORP (0001285819) (Subject)

    2/13/24 5:12:07 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care